Latest From GenoScience Pharma
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Biopharma financing totaled $3.7 billion in Q1 2012, $1 billion more than the previous quarter. A total of 22 M&As – with a potential value of $9.28 billion – were completed. Acquisitions of private biotechs structured with earn-outs were a highlight. About a quarter of the alliances involved Big Pharmas, with GlaxoSmithKline and Novartis taking the lead.
Funded in part by the Israeli government, BioLineRx believes it is about to score big with a cardiology drug being developed under FDA’s regulatory pathway for devices, as well as a schizophrenia candidate that could improve patients’ cognition.
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
- Therapeutic Areas
- Infectious & Viral Diseases
- Western Europe
- Parent & Subsidiaries
- GenoScience Pharma
- Senior Management
- Philippe Halfon, Pres.
- Contact Info
25-27 Rue Freidland
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.